SYMBIOTEC PHARMALAB (SYMBIOTEC) Share Price Falls 5.69% Today
- September 23, 2026
- Posted by: Harsh Piplani
- Category: News
SYMBIOTEC Share Price declined today, with the stock closing at Rs 1,057.40 versus the previous close of Rs 1,121.25. The move translates into a fall of Rs 63.85, or 5.69%, and places the company at a market capitalisation of Rs 7,443.75 Cr. In today’s trade, the shares opened at Rs 1,126.10, touched an intraday high of Rs 1,130.75 and a low of Rs 1,055.70. The supplied data confirms the price event, but it does not establish a company-specific catalyst. That makes the day’s move important for SYMBIOTEC Share Price Today readers who want to separate the observed decline from any unverified explanation. The stock also ended very close to the session low, which keeps attention on how selling pressure built through the day rather than on any single intraday swing.
For investors tracking SYMBIOTEC Stock News, the focus is on what the numbers show: a Mid Cap company, a large absolute price move, and a close near the day’s low. Univest is covering this as a price-action event first, then placing it in valuation and sector context so readers can judge the move in a disciplined way. The same approach also helps readers compare the session with other SYMBIOTEC Share Price updates without assuming an unverified reason behind the decline.
SYMBIOTEC PHARMALAB (SYMBIOTEC) Share Price Today: Price Action Analysis
| Metric | Value |
|---|---|
| Current Price | Rs 1,057.4 |
| Previous Close | Rs 1,121.25 |
| Today's Move | -Rs 63.85 (-5.69%) |
| Open | Rs 1,126.1 |
| High | Rs 1,130.75 |
| Low | Rs 1,055.7 |
| Turnover | Rs 19.7 crore |
| Market Capitalisation | Rs 7,443.75 crore |
| Market Cap Category | Mid Cap |
SYMBIOTEC Share Price Today shows a clear one-day decline from Rs 1,121.25 to Rs 1,057.40. The stock opened at Rs 1,126.10, traded up to Rs 1,130.75 and then weakened through the session to a low of Rs 1,055.70 before ending near that level. The day’s change of Rs 63.85 is the central fact in today’s move, and the close remained below the opening level as well as below the previous close. Turnover stood at Rs 19.7 Cr, which is the traded value recorded for the session. Because the company is a Mid Cap name with a market capitalisation of Rs 7,443.75 Cr, the move is relevant both for short-term stock news and for broader portfolio tracking. SYMBIOTEC Share Price today therefore reflects a sharp single-session decline that needs to be read alongside valuation and sector positioning rather than through any unverified trigger. For readers following SYMBIOTEC Share Price, the important point is that the entire session stayed under pressure after the early trade, and the close did not recover the opening zone. That naturally leads into a closer look at the company’s financial profile and what it implies for SYMBIOTEC Share Price analysis.
SYMBIOTEC PHARMALAB (SYMBIOTEC) Fundamental Analysis
| Metric | Value |
|---|---|
| Market Capitalisation | Rs 7,443.75 crore |
| P/E Ratio | 65.56x |
| P/B Ratio | 4.85x |
| ROE | 11.22% |
| ROCE | 12.41% |
| EPS | Rs 17.1 |
| Book Value Per Share | Rs 231.19 |
| Dividend Yield | 0% |
SYMBIOTEC PHARMALAB has a market capitalisation of Rs 7,443.75 crore and falls in the Mid Cap category, which gives readers a sense of company size before judging valuation. On valuation, P/E at 65.56x, P/B at 4.85x should be read against the sector and peer benchmarks rather than as a standalone signal. Profitability is represented by ROE of 11.22% and ROCE of 12.41%, helping investors compare shareholder returns and capital efficiency. Additional supplied metrics include EPS of Rs 17.1, book value per share of Rs 231.19, dividend yield of 0%, adding context to earnings, balance-sheet value and historical payout. Against the supplied same industry benchmark, these figures can be compared with benchmark median P/E of 31.75x, median ROE of 11.7%, median ROCE of 13.46%. These numbers explain the fundamental backdrop without converting the article into a buy or sell view. In this SYMBIOTEC Share Price update, the valuation gap is more useful as context than as a standalone conclusion, because the data available today only supports comparison, not attribution.
Sector and Industry Context
| Metric | Value |
|---|---|
| Sector | Healthcare |
| Industry | Pharmaceuticals & Drugs |
| Benchmark Scope | same industry |
| Company P/E Ratio | 65.56x |
| Benchmark Median P/E | 31.75x |
| Benchmark Average P/E | 49.54x |
| Benchmark P/E Range | 3.48x to 765.12x |
| Company P/B Ratio | 4.85x |
| Benchmark Median P/B | 3x |
| Benchmark Average P/B | 4.34x |
| Company ROE | 11.22% |
| Benchmark Median ROE | 11.7% |
| Benchmark Average ROE | 10.65% |
| Company ROCE | 12.41% |
| Benchmark Median ROCE | 13.46% |
| Benchmark Average ROCE | 13.26% |
| Company Market Capitalisation | Rs 7,443.75 crore |
| Benchmark Median Market Cap | Rs 748.47 crore |
| Benchmark Average Market Cap | Rs 14,370.3 crore |
SYMBIOTEC operates in the Healthcare sector and the Pharmaceuticals & Drugs industry, and the supplied benchmark uses the same industry universe of 200 companies. Within that set, SYMBIOTEC’s P/E of 65.56 is above the industry median of 31.75 and also above the industry average of 49.54. Its P/B of 4.85 is above the median of 3 but slightly above the average of 4.34. ROE at 11.22% is below the industry median of 11.7% but above the industry average of 10.65%, while ROCE at 12.41% is below both the median of 13.46% and the average of 13.26%. Market capitalisation of Rs 7,443.75 Cr is above the industry median market cap of Rs 748.47 Cr, though below the industry average of Rs 14,370.3 Cr. This sector and industry context is central to SYMBIOTEC Share Price because it shows how the stock sits in relation to the broader pharmaceuticals universe. For SYMBIOTEC Stock Analysis, the key point is that the day’s decline happened in a business segment where valuation and return ratios are meaningful comparison points.
Peer Comparison
| Company | Symbol | Market Cap (Cr) | P/E | P/B | ROE (%) | ROCE (%) |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries | SUNPHARMA | 4,48,195.77 | 36.58 | 5.12 | 14.85 | 19.11 |
| Divi's Laboratories | DIVISLAB | 2,50,389.96 | 84.8 | 14.04 | 16.19 | 21.51 |
| Torrent Pharmaceuticals | TORNTPHARM | 1,88,966.75 | 87.04 | 21.15 | 26.76 | 19.27 |
| Zydus Lifesciences | ZYDUSLIFE | 1,15,860.07 | 25.66 | 4.3 | 19.69 | 21.39 |
| Cipla | CIPLA | 1,11,888.39 | 33.1 | 3.17 | 11.83 | 16 |
Peer comparison helps place SYMBIOTEC Share Price in context. Compared with Sun Pharmaceutical Industries at P/E 36.58, P/B 5.12, ROE 14.85% and ROCE 19.11%, SYMBIOTEC trades at a higher P/E but a slightly lower P/B and lower return ratios. Versus Zydus Lifesciences, which shows a P/E of 25.66 and ROE of 19.69%, SYMBIOTEC again carries a richer earnings multiple. Cipla has a P/E of 33.1 and ROCE of 16%, both below SYMBIOTEC’s P/E and above its ROCE in the latter case. Divi’s Laboratories and Torrent Pharmaceuticals both show much higher P/E ratios than SYMBIOTEC, but also stronger P/B levels and better return metrics. In peer terms, SYMBIOTEC Share Price sits in a mixed zone: not the most expensive in the group, but above several large listed peers on earnings multiple, while trailing some of them on return ratios.
Why Investors Are Watching SYMBIOTEC
- SYMBIOTEC Share Price fell 5.69% today, with the stock closing at Rs 1,057.40 after a previous close of Rs 1,121.25.
- The day’s range was Rs 1,055.70 to Rs 1,130.75, with the open at Rs 1,126.10.
- Market capitalisation stands at Rs 7,443.75 Cr, placing the company in the Mid Cap category.
- The stock’s P/E is 65.56, P/B is 4.85, ROE is 11.22% and ROCE is 12.41%.
- In the healthcare peer set, SYMBIOTEC’s valuation sits above the industry median P/E of 31.75 and the industry median P/B of 3.
About SYMBIOTEC
SYMBIOTEC PHARMALAB is classified in the Healthcare sector and the Pharmaceuticals & Drugs industry. The company’s current market capitalisation is Rs 7,443.75 Cr, and its stock is listed under the symbol SYMBIOTEC. For readers searching SYMBIOTEC Company News, SYMBIOTEC Latest News or SYMBIOTEC Share Price Live, this article focuses on the verified market figures available today: price, valuation, returns and industry comparison. Univest is using only the supplied data to present the stock in a clean, event-led format.
Track SYMBIOTEC Share Price on Univest
Use SYMBIOTEC PHARMALAB (SYMBIOTEC) live share-price page,Univest top decliners screener,Univest market blogsto review live stock data, top decliners and related market analysis.
Readers can track SYMBIOTEC Share Price on Univest for live price updates, key valuation ratios, shareholding pattern, 52-week levels and market insights. Univest also brings together stock news, company context and benchmark comparisons in one place so users can follow SYMBIOTEC Share Price Today without switching between multiple sources.
Frequently Asked Questions
Why did SYMBIOTEC Share Price fall today?
Ans. SYMBIOTEC Share Price fell 5.69% today to Rs 1,057.40. The supplied data confirms the decline, but it does not establish a company-specific catalyst or reason for the move. The previous close was Rs 1,121.25.
What is the current SYMBIOTEC Share Price Today?
Ans. The current SYMBIOTEC Share Price is Rs 1,057.40. It compares with the previous close of Rs 1,121.25, showing a day-wise fall of Rs 63.85 in today’s session. The previous close was Rs 1,121.25.
What does SYMBIOTEC market capitalisation show?
Ans. SYMBIOTEC has a market capitalisation of Rs 7,443.75 Cr and is placed in the Mid Cap category. Market capitalisation indicates company size, not quality or future performance. The company operates in the Healthcare sector.
How does SYMBIOTEC look on valuation?
Ans. SYMBIOTEC trades at a P/E of 65.56 and a P/B of 4.85. In the same industry benchmark, those levels sit above the median P/E of 31.75 and median P/B of 3.
What do SYMBIOTEC EPS and book value mean?
Ans. SYMBIOTEC EPS is Rs 17.1 and book value is Rs 231.19 per share. EPS measures earnings attributable to each share, while book value shows the accounting net worth behind each share.
